title: [Advances treatment of osteoporosis: new molecules, new strategies].
abstract: Practitioners already have a wide range of effective drugs for the treatment of osteoporosis, but new options are needed to prevent fractures in patients with this chronic and disabling disease. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss, based on inhibition of bone resorption by osteoclasts (anti-RANK ligand antibodies and cathepsin K inhibitors) or stimulation of bone formation by osteoblasts (anti-sclerostin antibodies). These future treatments (anti-RANK ligand antibodies should shortly be available) will add osteoporosis to the growing list of disorders amenable to targeted biotherapies.
authors: Hôpital Lariboisière, 41 bid de la Chapelle, 75475 Paris cedex 10. philippe.orcel@lrb.aphp.fr
authors: Philippe
authors: P
authors: Orcel
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002755:Choice Behavior / Q000502:physiology; D000069448:Denosumab; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004704:Endocrinology / Q000379:methods* / Q000639:trends*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D053245:RANK Ligand / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
chemical_list: D045930:Anabolic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D015507:Drugs, Investigational; D053245:RANK Ligand; D000069448:Denosumab